Dana-Farber Targeted Protein Degradation Webinar Series

Targeted protein degraders (TPDs) are transforming drug discovery, and HESI Global’s precompetitive, multi-sector Targeted Protein Degrader Safety Committee is building science-based, actionable approaches to support safer next-generation therapeutics.

Webinar (Hosted by Dana-Farber) — March 5, 12 - 1 pm EST
Safety of Targeted Protein Degraders: HESI Global’s Collaborative Framework and Portfolio Highlights

Hear from:

• Cissy Li, PhD (HESI Global) – Program Manager advancing multi-stakeholder, translational safety research across TPD and ADC programs
• James Sidaway, PhD (ApconiX) – Head of Safety Science Group; mechanistic toxicologist with 25+ years in pharma, pioneering advanced in vitro safety models
• Benjamin Elser, PhD (Bristol Myers Squibb) – Senior Scientist in DART; developing in vitro methods to assess teratogenic risk and contributing to HESI’s CRBN-focused collaboration

The session will spotlight work from HESI Global’s Cereblon (CRBN) Workgroup, including an overview of current practices for safety testing of Cereblon-Recruiting TPDs and ongoing efforts linking neosubstrate degradation to human-relevant in vitro teratogenicity signals.

More details + registration: https://www.danafarbertargetedproteindegradation.org/